Valuation: AbbVie Inc.

Capitalization 365B 312B 288B 271B 504B 34,196B 517B 3,369B 1,325B 16,331B 1,371B 1,341B 58,335B P/E ratio 2026 *
23.2x
P/E ratio 2027 * 18.3x
Enterprise value 417B 356B 329B 310B 576B 39,050B 591B 3,848B 1,513B 18,649B 1,565B 1,532B 66,616B EV / Sales 2026 *
6.22x
EV / Sales 2027 * 5.59x
Free-Float
96.39%
Yield 2026 *
3.36%
Yield 2027 * 3.49%
1 day-0.71%
1 week-0.11%
Current month-5.07%
1 month-6.01%
3 months-6.47%
6 months-10.35%
Current year-9.64%
1 week 203.01
Extreme 203.01
214.1
1 month 201.66
Extreme 201.6634
224.37
Current year 201.66
Extreme 201.6634
237.11
1 year 168.54
Extreme 168.54
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/01/2003
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 68 01/01/2013
Change 5d. change 1-year change 3-years change Capi.($)
-0.71%-0.11%+17.95%+26.91% 365B
-1.06%+0.27%+26.92%+147.78% 832B
-0.21%-1.25%+56.83%+43.25% 573B
+0.48%-0.75%+29.45%+14.12% 322B
-0.14%+0.13%+45.14%+25.95% 313B
-1.05%-0.58%+51.74%+3.95% 297B
+0.02%+0.82%+36.11%+38.11% 292B
-0.34%+2.12%+22.32%+39.13% 189B
+0.03%-0.78%+34.16%+66.96% 173B
+3.42%+4.32%-43.73%-57.15% 166B
Average +0.15%-0.52%+27.69%+34.90% 352.05B
Weighted average by Cap. -0.00%-0.60%+32.35%+54.53%

Financials

2026 *2027 *
Net sales 67.06B 57.29B 52.82B 49.85B 92.63B 6,279B 94.98B 619B 243B 2,999B 252B 246B 10,712B 72.49B 61.93B 57.1B 53.89B 100B 6,788B 103B 669B 263B 3,242B 272B 266B 11,580B
Net income 16.23B 13.87B 12.79B 12.07B 22.42B 1,520B 22.99B 150B 58.88B 726B 60.92B 59.63B 2,593B 19.78B 16.9B 15.58B 14.71B 27.33B 1,853B 28.02B 183B 71.77B 885B 74.25B 72.68B 3,160B
Net Debt 51.84B 44.29B 40.84B 38.54B 71.61B 4,854B 73.43B 478B 188B 2,318B 195B 190B 8,281B 40.26B 34.39B 31.71B 29.93B 55.61B 3,770B 57.02B 371B 146B 1,800B 151B 148B 6,431B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
13/04/26 206.47 $ -0.71% 7,532,517
10/04/26 207.94 $ -2.10% 4,633,169
09/04/26 212.40 $ +0.38% 4,478,093
08/04/26 211.59 $ +2.53% 5,477,736
07/04/26 206.37 $ -0.15% 8,801,612
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
206.47USD
Average target price
249.00USD
Spread / Average Target
+20.60%

Quarterly revenue - Rate of surprise